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Summary:
The purpose of this trial was to study feasibility and
tolerance of a dose-intensive multicyclic alternating
induction chemotherapy with repeated stem cell support
in a series of 43 metastatic breast cancer patients.
Anthracycline-naive patients (n = 21) received cyclopho-
sphamide 2.5 g/m2 plus doxorubicin 80 mg/m2 alternat-
ing every 14 days with paclitaxel 200–350 mg/m2 plus
cisplatin 120 mg/m2. Patients who had previously
received anthracyclines (n = 22) received cisplatin 120
mg/m2 plus etoposide 600 mg/m2 alternating with paclit-
axel 200–350 mg/m2 plus ifosfamide 8 g/m2. Peripheral
blood stem cells were infused after every course except
the first, with a median CD34+ dose of 2.1  106/kg per
cycle. Positive selection of CD34+ cells was performed
in good mobilizers. The median number of cycles
administered was six (4–8), and the time interval
between them was 17 days. Median summation dose
intensities (SDI) actually administered for the CA-TP
and PE-TI protocol were 4.95 and 4.69, respectively
(87% of scheduled SDI). There were 15 complete (35%)
and 21 partial responses (49%), for an overall response
rate of 84% (95% CI, 73%–95%). Infection or neutro-
penic fever occurred in 50% of the cycles. There was
one treatment-related death. After a median follow-up
of 26 months, the median event-free-survival was 12
months (95% CI: 10–14) and overall survival was 31
months. These high dose-intensity induction treatments
seem to be feasible with sequential stem cell support.
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The dose–response relationship in breast cancer (BC) ther-
apy has been a matter of controversy for the last two dec-
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ades. Extensive literature reviews by Hryniuk et al1,2 have
found dose intensity to be correlated with response rate and
survival. This effect has been considered in the rationale
of many clinical trials that attempted to improve long-term
survival in metastatic BC by delivering single courses of
high-dose chemotherapy (HDC). Despite some promising
data derived from phase II trials, results of the randomized
studies published thus far have failed to show a sound
clinical benefit for single autografts.3–5
There might be other ways to take advantage of the dose-
intensity principle. In vitro, repeated doses of chemotherapy
cause more cell kill than single doses, even though the total
amount of drug administered is the same.6 The classical
model of Gompertzian kinetics provides a possible expla-
nation for this fact through rapid compensatory re-growth
of the resistant clones not eradicated by HDC.7 The spread
of the cytotoxic effect over a longer period of time might
increase cell kill and reduce the probability of drug resist-
ance.8 Multicyclic treatment schemes appear to take advan-
tage of the inherent time-dependant responsiveness of most
cancer tissues.
Autologous peripheral blood stem cell infusions have
been extensively used to support single courses of HDC.
Nonetheless, their possible use in programs of multicyclic
non-myeloablative dose-intense chemotherapy has been
little explored.9–12 In November 1995, the Department of
Oncology of University of Navarra, Spain, initiated a feasi-
bility study that included a biweekly, alternating, dose-
intensive chemotherapy regimen. The results observed in
the first 43 patients with metastatic BC are presented in
this report.
Materials and methods
Women with histologically proven metastatic BC were
evaluated for study entry. An ECOG performance status of
0–1, age less than 65 years, and no evidence of cardiac,
pulmonary, liver or renal impairment were required. All
patients gave written informed consent according to insti-
tutional policy before entering the study. Patients
presenting with brain metastases, leptomeningeal disease,
or bone marrow involvement, as well as patients previously
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Table 1 Chemotherapy regimen
Prior anthracyclines: No prior anthracyclines:
PE-TI protocol CA-TP protocol
Cycle A: Cisplatin 120 mg/m2 + Cyclophosphamide 2.5 g/m2 +
Etoposide 600 mg/m2 Doxorubicin 80 mg/m2
Cycle B: Paclitaxel 200–340 mg/m2a Paclitaxel 200–350 mg/m2a +
+ Cisplatin 120 mg/m2
Ifosfamide 8 g/m2
aSee text for dose-escalating strategy.
treated with chemotherapy for metastatic disease (including
anthracycline-containing regimens and HDC) were not
excluded.
Pretreatment assessment included medical history and
physical examination, chest-X-ray, thoraco-abdominal CT
scan, bone scan, brain MRI, EKG, LVEF, respiratory func-
tion tests, metabolic panel, serum tumor markers (CA15.3
and CEA), and HIV, CMV, HbsAg, HVC titers. A positron
emission tomography (PET) with 18-fluorodeoxiglucose
was performed before treatment in some cases. Bone mar-
row biopsy and aspiration were performed in the presence
of multiple bone metastasis and/or peripheral cytopenia.
Treatment
A double-lumen Hickman central catheter was placed
before the start of treatment. The chemotherapy regimen
and treatment schedule are shown in Table 1 and Figure 1.
Treatment included six or eight alternating cycles with a
scheduled interval of 14 days between treatments. The
interval was lengthened if the platelet count was below 40
 109/l or if there was an unresolved WHO grade 3 or 4
non-hematological toxicity, but dose reductions were not
scheduled. Patients were divided into two groups according
to prior treatment with anthracyclines (Table 1).
Group 1: Twenty-two patients with prior anthracycline-
based chemotherapy were treated according to the PE-TI
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Figure 1 Treatment schedule. Cells were reinfused 48 h after chemo-
therapy except after the first cycle (syringes in the diagram). A = cycle
A; B = cycle B; G = G-CSF; APH = leukapheresis; POS SEL = posi-
tive selection.
protocol. This protocol consisted of cisplatin 30 mg/m2 i.v.
twice daily on days 1 and 2 (total dose: 120 mg/m2) plus
etoposide 150 mg/m2 i.v. twice daily on days 1 and 2 (total
dose: 600 mg/m2 i.v.) (cycle A), alternating every 2 weeks
with paclitaxel 200–350 mg/m2 i.v. (see text below) once
daily on day 1 plus ifosfamide 2 g/m2 i.v. twice daily on
days 1 and 2 (total dose: 8 g/m2) (cycle B). Paclitaxel pre-
medication included dexamethasone, cimetidine, and
diphenhydramine. Ifosfamide was administered with
hyperhydration and 2-mercapto-ethane sulfonate (Mesna)
uroprotection.
Group 2: Twenty-one anthracycline-naive patients were
treated according to the CA-TP protocol. This protocol
included cyclophosphamide 625 mg/m2 i.v. twice daily on
days 1 and 2 (total dose: 2.5 g/m2) plus doxorubicin 20 mg/m2
i.v. twice daily on days 1 and 2 (total dose: 80 mg/m2) (cycle
A), alternating with paclitaxel 200–350 mg/m2 (see text
below) i.v. on day 1 plus cisplatin 30 mg/m2 i.v. twice daily
on days 1 and 2 (total dose: 120 mg/m2) (cycle B). Cyclo-
phosphamide was administered with hyperhydration and
Mesna uroprotection.
Ondansetron, ACTH, and metoclopramide with lora-
zepam were given to control emesis. Patients received esca-
lating doses of paclitaxel (without intrapatient dose
escalation). The first 12 patients received 200 mg/m2; the
next five patients 250 mg/m2; nine patients received 300
mg/m2, and the 17 last patients received 350 mg/m2.
Finally, the maximum tolerated dose was established at 300
mg/m2 (see below).
Hematopoietic support
The stem cells were mobilized with G-CSF, 5–12
g/kg/day subcutaneously beginning on day 9. Peripheral
blood CD34 cell counts were performed daily from day
13. The optimal day for cell collection was decided on an
individual basis, considering CD34, leukocyte, and platelet
counts. Collections were performed with continuous flow
apheresis machines (Cobe Spectra; Cobe BCT, Barcelona,
Spain) or CS3000plus (Baxter, Barcelona, Spain), pro-
cessing two to five blood volumes. The first 18 patients
were mobilized after every course. A single leukapheresis
was performed in each mobilization, and the whole apher-
esis product was infused after the next course. The rationale
for this was two-fold: first, to avoid collection of contami-
nating tumor cells through an ‘in vivo purging’ effect in
this population of patients with active metastatic disease
not in remission;13 second, to procure high doses of stem
cells to minimize hematopoietic damage. In February 1997,
an interim analysis showed that a dosage between 2 and 4
 106/kg CD34 cells was optimal.14 From this point,
patients undergoing excellent mobilizations (peak CD34+
cells in peripheral blood greater than 90 cells/mm3) were
considered for positive selection of CD34+ cells. In this
case, two to three consecutive leukaphereses were perfor-
med, and cells were selected with an Isolex 300i (Baxter)
device according to manufacturer’s recommended pro-
cedures. The positive fraction was divided for the support
of as many courses as possible, with the goal of delivering
approximately 2  106/kg CD34+ cells per cycle. Patients
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with less than excellent mobilizations were repetitively
mobilized in every cycle as stated above (Figure 1).
Cellular products were infused 48 h after the end of every
chemotherapy course. G-CSF 5 g/kg/day subcutaneously
was administered from days 6 to 10 to promote granulocyte
recovery, even if it was not necessary to mobilize the
patient. The first course of the program was given without
cellular support.
Dose-intensity calculation
Dose intensity (DI) is the amount of drug delivered per unit
time in weeks. This parameter, first introduced by Hryniuk
and Bush1 in 1984, has been used to test the dose–response
relationship in different malignancies, as well as to compare
different chemotherapy regimens. A new parameter, sum-
mation dose intensity (SDI), integrates the contribution of
each individual agent within a combination regimen2 and
shows a stronger correlation with favorable outcome than
the classical DI parameter. The SDI calculations are shown
in Table 2. The planned SDI of the CA-TP combination
protocol was 5.42 SDI units, based on a 14-day treatment
schedule and considering the finally recommended dose of
300 mg/m2 of paclitaxel. The planned SDI of PE-TI combi-
nation was 5.16 SDI units. We assigned to ifosfamide the
dose-intensity value of 1111 mg/m2/week of cyclophos-
phamide, extrapolating the equivalence between these
two drugs.15
Response assessment
Clinical and radiologic tumor response was evaluated
according to the International Union Against Cancer
Table 2 Dose intensity calculations
Regimena RDI UDI SDI
(mg/m2/week) (mg/m2/week)
CA-TP
Cyclophosphamide 625 650 625/650 = 0.96
Doxorubicin 20 12.5 20/12.5 = 1.6
Paclitaxel 75 50 75/50 = 1.5
Cisplatin 30 22 30/22 = 1.36
Total SDI 5.42 UDIs
PE-TI
Paclitaxel 75 50 75/50 = 1.5
Ifosfamide 1111b 650c 1111/650 = 1.70
Cisplatin 30 22 30/22 = 1.36
Etoposide 150 640 150/640 = 0.44
Total SDI 5.16 UDIs
RDI = relative dose-intensity in mg/m2/per week; UDI = unit of dose-
intensity. Dose-intensity required to produce a 30% complete response
plus partial response (CR+PR) rate when this agent is used alone; SDI =
summation dose-intensity.
Dose-intensity calculations according to Hryniuk et al.2 Paclitaxel dose-
intensity has been calculated according to the finally recommended dose
of 300 mg/m2.
aAlternating biweekly cycles. Note that the interval between doses of the
same drug is 4 weeks.
b1111 mg/m2/wk = the equivalent dose of cyclophosphamide from 2
g/m2/week of ifosfamide.20
c650 = 1 UDI of cyclophosphamide.
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(UICC) criteria.16 In addition, serum chemistries and serum
markers were conducted biweekly before every cycle.
Response was assessed every two courses till the end of the
program by the same imaging technique as used at baseline.
Patients in complete response after six cycles of chemo-
therapy were evaluated for consolidation therapy as out-
lined below. Patients not achieving complete response after
six cycles received two additional cycles of chemotherapy.
In patients with bone metastasis, partial response was
defined as pain relief along with stable or improved bone
scan findings and complete or near complete normalization
of serum markers at the completion of therapy. Complete
response was defined as complete normalization of bone
scan. When evaluation of residual lesions on CT scan was
difficult, abdominal MRI (in the case of liver metastasis)
or PET were performed.
Toxicity evaluation and supportive care
Organ-system toxicity was graded according to the criteria
of Petersen et al17 for intensive chemotherapy with stem
cell transplantation. If the toxicity found in these series had
been graded according to the World Health Organization
system,18 all patients would have experienced grade 4 hem-
atological toxicity and grade 3 and 4 toxicities in several
organs. Emesis and hematologic toxicity were evaluated
according to the WHO criteria18 because Petersen’s criteria
were not applicable.
Patients were managed on an outpatient basis between
treatments. Patients with febrile granulocytopenia, docu-
mented infections, or non-infectious complications were
hospitalized. Patients received transfusions of packed red
blood cells if the hemoglobin level was less than 9 g/dl and
a single donor apheresis unit of platelets when the platelet
count was less than 10  109/l. All the hemoderivates
underwent prior filtration for leukocyte depletion.
Consolidation therapy
Consolidation treatment was decided on an individual basis,
taking into account the extent of initial disease and the
response obtained at the completion of the sequential inten-
sive chemotherapy regimen (SICT). All patients with areas
of initial bulky disease were evaluated for radiation therapy.
HDC with stem cell support and adjuvant hormonal therapy
or adoptive immunotherapy were offered to responding
patients after SICT.
Statistics
Descriptive data are given as median values, with the range
in parenthesis. Event-free survival was calculated from the
first day of the SICT regimen until the appearance of dis-
ease progression or death. Overall survival was calculated
from the first day of the SICT regimen until the date of
death or the last follow-up. Both survival curves were cal-
culated with the Kaplan–Meier method and compared with
the log-rank test. Categorical variables (ie different charac-
teristics in responding patients) were compared with the
Chi-square method. Kolmogorov–Smirnov test with Lillie-
for’s adjustment was used to test the normal distribution.
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The Spearman rank correlation test was used to explore the
relationship between CD34+ cell dosage and treatment
delay and also the correlation between CD34+ cell counts
and the cycle used for mobilization (ordinal variable with
seven categories). Comparisons between two groups of
non-normally distributed variables (delay in patients receiv-
ing CA-TP or PE-TI protocols; delay in patients having
received or not previous stem cell transplantation) were
made with the Mann–Whitney test. For comparisons among
multiple groups (delay in patients receiving 0 to four
previous chemotherapy lines), the Kruskall–Wallis test
was used. Both database management and statistical
calculations were done with the SPSS 7.5 package.
Results
Patients
Forty-three females with metastatic BC participated in this
study between November 1995 and February 1998. Results
are available for 43 patients. A heavy disease burden
characterized the patient profile in most of the cases.
Pretreatment characteristics are specified in Table 3.
Dose-intensity
Forty-three patients completed the treatment plan as sched-
uled. The median number of cycles administered was six
(range, 4–8), and the median time interval between cycles
was 17 days. The overall median SDI actually administered
in the CA-TP protocol was 4.95 SDI units, which represents
a mean of 87.4% of the planned SDI. The overall SDI given
of the PE-TI protocol was 4.69 SDI units, representing a
Table 3 Pretreatment characteristics of patients
Characteristic Number Percent
Size of patient population 43
Age, median (range) 44 (23–61)
Performance status (ECOG) (range) 0 (0–1)
Previous adjuvant chemotherapy 32/43 74
Number of prior CT lines, median (range) 2 (0–5)
Prior CT for metastatic disease 17/43 39
Number of prior CT lines for metastasis, 1 (1–4)
median (range)
Previous anthracyclines 22/43 51
Previous HDCa 12/43 28
Adjuvant setting 5/12
Metastatic setting 7/12
Number of metastatic sitesb
1 18/43 41
1 25/43 59
Sites of metastases:
Breast +/− locoregional relapse 7/43 16
Distant lymph node metastases 7/43 16
Lung/Pleura 15/43 35
Liver 15/43 35
Bone/bone marrow 29/43 67
CNS/Leptomeningeal 7/43 16
CT = chemotherapy; HDC = high-dose chemotherapy.
aHDC had already been for metastatic disease in seven patients.
bSee Table 4 for details on sites of disease.
mean of 86.7% of the planned SDI. These calculations were
done on a patient-by-patient basis, considering the dose of
paclitaxel assigned to each one.
Results in cellular support
A total of 154 mobilizations were performed. The median
peak CD34+ count in peripheral blood was 33  106/l cells
(range, 1.4–940). In patients repeatedly mobilized, the
intensity of the mobilization response progressively
declined along the treatment (Figures 2 and 3). Both the
peak peripheral blood CD34+ count and the number of
CD34+ cells collected in a single apheresis showed a sig-
nificant inverse rank correlation with the ordinal number of
the cycle used for mobilization (Rs = −0.48 and P  0.0005
in both cases). The median dose of CD34+ cells infused per
cycle was 2.1  106/kg (range, 0.1–91). Since the positive
selection procedure was available, 25 patients entered the
SICT program and 14 of these underwent positive selection
following our eligibility criteria (sufficient mobilization to
make likely the support of several courses with the positive
fraction from a single selection). The positive fraction could
be distributed for the support of a median of four courses
(range, 2–6), with a median CD34+ dose per cycle of 1.8
 106/kg (range, 0.9–2.5). Among patients not undergoing
positive selection, a median of five mobilizations per
patient were performed.
The median delay for the administration of the next
course over the scheduled interval of 2 weeks was 3 days
(range, 0–35), in most cases due to delay in reaching hema-
topoietic recovery or optimal mobilization. There was a
non-linear relationship with a significant inverse correlation
between CD34+ cell dose infused and the delay for the
administration of the next course (Rs = −0.29; P  0.001)
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Figure 2 Median peak peripheral blood CD34+ cell count achieved
according to the cycle used for mobilization. Only results from patients
repeatedly mobilized are included (see text).
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Figure 3 Median number of CD34+ cells collected in a single apheresis
according to the cycle used for mobilization. Only results from patients
repeatedly mobilized are included (see text).
in the courses supported with non-selected aphereses pro-
ducts (see Figure 4). This correlation was not significant if
only positive fraction-supported cycles were considered (Rs
= −0.019; P = 0.93). The delay for the next cycle was not
significantly related to the type of SICT administered (CA-
TP or PE-TI), the number of chemotherapy lines received
prior to the SICT, the previous treatment with stem cell
transplantation, or the type of cellular product used for
hematopoietic support (unselected apheresis product or
positive fraction).
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Figure 4 Relationship between the CD34+ cell dose infused after one
cycle and the delay for the administration of the following one. The last
course of each patient has been excluded from this analysis.
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Responses
Forty-three patients were evaluable for response. There
were 15 (35%) complete responses, 21 (49%) partial
responses, two (5%) patients with stable disease and five
(12%) progressions, for an overall response rate of 84%
(95% confidence interval, 73%–95%). All non-responding
patients had extensive disease, with more than two sites
of metastasis, including CNS in three cases. Among eight
patients presenting central nervous system metastasis (with
other organs affected in six), there were two complete and
one partial response. Of interest, the overall response rate
for liver metastasis was 80%. There was no significant dif-
ference in response rate between CA-TP (seven complete
and 11 partial, among 21 patients) and PE-TI treated
patients (eight complete and 10 partial among 22).
Toxicity
Times to neutrophil and platelet recovery are not reported,
as full blood counts were not performed on a daily basis,
except when patients were hospitalized due to compli-
cations. The median delay between cycles (see data above)
and hemoderivate requirement have been used to estimate
hematologic toxicity. A median of 3.5 (range, 0–49) platelet
transfusions per patient and 16.5 (range, 4–35) units of red
blood cells per patient were required.
Neutropenic fever occurred in 50% of the cycles. Posi-
tive blood cultures were reported in 14 patients (32%),
excluding blood cultures positive for Staphylococcus
epidermidis.
Organ system toxicities are summarized in Table 4. Two
patients developed acute renal failure and required renal
dialysis, and one patient developed paralytic ileus and
required nasogastric aspiration. One patient developed
grade II cardiotoxicity with a decrease of the left ventricular
ejection fraction down to 30%. There was no ifosfamide-
related hemorrhagic cystitis or severe encephalopathy. Nine
patients developed WHO grade 3 nausea/vomiting, but this
never hampered the delivery of the treatment program.
Generalized fatigue was present in all patients and was
cumulative. Seven patients experienced mild transient
bradycardia.
Three cases of acute reversible encephalopathy, probably
Table 4 Toxicity
Grade II Grade III
Cardiac 1 0
Bladder 0 0
Renal 2 2
Pulmonary 0 0
Hepatic 1 0
CNS 0 0
Stomatitis 2 0
Gastrointestinal 1 1
CNS = central nervous system.
Toxicity according to Peterson et al criteria.18
Note: Grade I toxicity is defined as mild symptoms always reversible with-
out treatment (similar to WHO grade I toxicities). Data not reported. Grade
IV regimen-related toxicity is defined as fatal toxicity.
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associated with paclitaxel,19 were observed at the 350
mg/m2 dose. These patients developed severe hypotension
and loss of consciousness that was reversible and non-fatal
in all cases. After these events, we concluded that the
maximum tolerated dose of paclitaxel for these programs
was 300 mg/m2.
There was one treatment-related death due to multior-
ganic failure of probable septic origin. CT scan documented
progression of disease.
Consolidation therapy
Patients received different modalities of consolidation ther-
apy, depending on the response observed. After the com-
pletion of chemotherapy, 19 patients received irradiation to
sites of initial bulky disease or residual lesions that had
responded to chemotherapy. Three patients achieving com-
plete response received a single course of HDC as consoli-
dation. Nine responding patients entered a program of
adoptive immunotherapy, and six patients received hor-
monotherapy. Eight patients did not receive any type of
consolidation therapy.
Outcome
After a median follow-up of 26 months (range, 16–44),
median event-free survival was 12 months (95% CI, 10–
14) (Figure 5). The 3-year overall survival rate was 43%,
with a median survival time of 31 months (Figure 6).
Median time to progression was 13 months (95% CI, 11–
15). At the time of this analysis, 18 patients (41%) have
died of disease. Twenty-three patients (53%) are still alive,
seven of them (16%) with no evidence of disease. Two
patients in complete response died without evidence of dis-
ease, due to heart failure and sudden death of unknown
origin, respectively.
Five of the seven patients alive with no evidence of dis-
ease obtained complete remision (CR) with the SICT and
were subsequently irradiated. The other two patients
obtained partial remision (PR) after SICT and received
radiotherapy as consolidation on the remaining hepatic
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Figure 5 Overall survival.
lesions; they have remained disease-free for over 20 months
of follow-up. Sixteen patients are alive with disease, and
some of them have received further chemotherapy or
hormonal therapy after SICT.
We found no statistically significant differences in event-
free survival or overall survival among CATP- and PETI-
treated patients, among patients who achieved complete
response and those who did not, among patients previously
treated with chemotherapy and chemotherapy-naive
patients, among patients previously treated with HDC
or not, or among patients receiving different doses of
paclitaxel.
Sites of relapse after SICT
Median duration of response was 12 months (95% CI, 11–
28). Recurrences have been observed predominantly in
areas with previous bulky disease (75% of cases). Eight of
31 (25%) patients have relapsed in areas that were not
involved initially, five of them with new onset brain met-
astasis. Fourteen of the 19 patients who were irradiated are
still alive with no evidence of disease progression in the
areas treated with irradiation.
Discussion
The patients in this study received multiple cycles of
chemotherapy with higher than conventional, but far from
myeloablative, doses of several drugs at short time inter-
vals. An alternating schedule was chosen in order to allow
the early introduction of as many active non-cross-resistant
drugs as possible. Although any of the chemotherapy
courses used in this protocol might have been safely admin-
istered without any hematopoietic support, its quick rep-
etition within a 2-week interval would have probably lead
to cumulative marrow toxicity. Thus, we expected this regi-
men to be tolerated with strong hematopoietic support with
both PBSC and G-CSF. The chemotherapy schedule was
discontinued in only one patient due to cardiotoxicity.
Median interval between cycles was 17 days, only 3 days
more than the planned biweekly interval. The adminis-
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Figure 6 Event-free survival.
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tration of this dose-intensive regimen with repeated stem
cell support seems to be feasible. We had also come to
the same conclusion after testing this protocol in advanced
ovarian carcinoma and Ewing’s sarcoma.20,21 Previous
reports have shown the feasibility of different multicyclic
dose-intensive regimens with stem cell support.9–12
The dose of CD34+ cells administered inversely corre-
lated with the delay over the scheduled 2-week interval
between cycles. In a multivariate analysis, we found the
CD34+ cell dose to be a significant predictor of the actual
administered dose intensity.22 Nevertheless, above certain
threshold values of cells, further increases in the CD34 dose
may not lead to further significant decreases in the inter-
val.14,22 A similar effect has been described in single auto-
grafts with stem cell support, where recoveries are never
reached before certain points (8 to 9 days post infusion),
regardless of the CD34+ cell dose administered.23 More-
over, in our program, an interval shorter than 2 weeks was
not intended. These are reasonable explanations for the lack
of correlation between CD34+ cell dose and delay in the
group supported with positive fraction, where the CD34+
cell dose was planned prior to cryopreservation.
Contamination of the graft by malignant cells is a com-
mon occurrence in metastatic breast cancer.24–27 Most of
the experience in this area is based on the study of apheresis
products collected when patients who have responded to
previous induction chemotherapy are about to be intensi-
fied. The patients in our series were mobilized during the
recovery from induction cycles, when active metastatic dis-
ease was still present and the risk of contamination would
theoretically be higher. Although the actual prognostic sig-
nificance of contaminating tumor cells remains contro-
versial,24–27 we considered it appropriate to infuse an
unselected cellular product immediately after the next one
or two courses following collection, but not at a later time,
when the tumor burden could have been markedly reduced
by the treatment. In most of our patients, enough progeni-
tors to support the whole SICT program could have been
collected with a short series of leukaphereses in a single
mobilization. Nevertheless, we only performed this pro-
cedure when positive selection of CD34+ cells was possible.
Hematopoietic support with selected products was associa-
ted with an excellent observance of the dose intensity plan,
with a median delay of 1.5 days in this group. The distri-
bution of the positive fraction from a single selection for
the support of several courses contributes to the economical
feasibility of this program. On the other hand, patients not
undergoing cellular selection were mobilized repetitively
after each cycle, in an attempt to perform ‘in vivo purging’
of the products.11,13 We could mobilize the patients up to
seven times without relevant compromise in the dose
intensity.
HDC with stem cell support has been widely used as
consolidation treatment after induction with conventional-
dose chemotherapy. Alternatively, the aim of our protocol
was to test a high dose-intensity protocol as induction treat-
ment. We used the SDI method for the DI calculations.2
Hryniuk et al have reported a 30% increase in the overall
response rates in metastatic BC by SDI increases of one
unit. Of note, according to Hryniuk’s literature review,
none of the comparative trials testing dose intensity in con-
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ventional chemotherapy for metastric BC has targeted a
sufficient difference in SDI among arms (1.5 units) to
expect a meaningful increase in CR rate (15%) or in median
survival time (6 months). The maximum SDI reached by a
CMF combination in a controlled trial is 1.98.28 By admin-
istering GM-CSF, Ardizzoni et al29 escalated the SDI of
the FEC regimen up to 2.11 units. The projected SDI of
our CA-TP and PE-TI regimens for the recommended dose
of paclitaxel are 5.42 and 5.16, respectively, higher than
that of any multicyclic chemotherapy tested in randomized
trial for first-line treatment of metastatic BC. Moreover, the
mean dose intensity actually administered in our series was
above 85% for both regimens, showing that these levels of
dose intensity are a realistic goal.
We found that consolidation treatment has probably been
of benefit in our series. Fourteen of 19 patients who were
irradiated after SICT are alive without evidence of pro-
gression at last follow-up. In addition, the seven patients
who remain alive without evidence of disease after a
median follow-up of 25 months received irradiation over
predominant sites of disease after obtaining complete or
partial response. In our series, 75% of the areas that showed
a subsequent recurrence (or regrowth of persistent disease
after chemotherapy) had been initially involved. Carter et
al30 reported how the addition of radiation to HDC
appeared to reduce the failure rate at initial sites of disease
(28% without consolidation radiotherapy vs 62% with it)
and improve event-free survival (21% vs 31%) and overall
survival (16% vs 30%).
Most patients have received further chemotherapy after
disease progression was documented. This circumstance
should be borne in mind on interpreting the overall survival
results of our series. Docetaxel and/or vinorelbine have
been the most frequently used drugs. In general, hematolog-
ical tolerance has been good despite previous SICT, without
prolonged delays between subsequent cycles.
In this series, a strong hematopoietic support made feas-
ible a multicyclic chemotherapy program with substantially
high-dose intensity. The response results achieved in a scar-
cely selected population warrant further comparison with
other therapeutic approaches for advanced BC.
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